Recent Quotes (30 days)

You have no recent quotes
chg | %

Antibe Therapeutics Inc  

(Public, CVE:ATE)   Watch this stock  
Find more results for ATE
+0.010 (5.88%)
Oct 21 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.17 - 0.18
52 week 0.10 - 0.27
Open 0.17
Vol / Avg. 236,300.00/65,660.00
Mkt cap 16.82M
P/E     -
Div/yield     -
EPS -0.05
Shares 93.42M
Beta -0.08
Inst. own     -
Nov 24, 2016
Q2 2017 Antibe Therapeutics Inc Earnings Release (Estimated) Add to calendar
Sep 13, 2016
Antibe Therapeutics Inc at Rodman & Renshaw Global Investment Conference
Aug 29, 2016
Q1 2017 Antibe Therapeutics Inc Earnings Release
Jul 29, 2016
Q4 2016 Antibe Therapeutics Inc Earnings Release

Key stats and ratios

Q2 (Jun '16) 2016
Net profit margin -42.07% -59.30%
Operating margin -43.77% -78.80%
EBITD margin - -70.33%
Return on average assets -43.62% -49.98%
Return on average equity -90.01% -104.31%
Employees 3 -
CDP Score - -


15 Prince Arthur Ave
+1-905-5705103 (Phone)

Website links


Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery.

Officers and directors

Walter M. Macnee Independent Chairman of the Board
Age: 60
Daniel Legault J.D. President, Chief Executive Officer, Secretary, Director
Age: 56
John L. Wallace Ph.D. Founder, Chief Scientific Officer, Director
Age: 57
Alain S Wilson Chief Financial Officer
Jeremy Grushcow Executive Vice President - Strategic Development
David Vaughan Chief Development Officer
Age: 63
Samira Sakhia CPA Director
Yung Wu Director
Roderick J. Flower Ph.D. Independent Director
Age: 69
Jonathan Ross Goodman Independent Director
Age: 47